Notable Labs reports FY2023 net loss of $11.3M; cash of $8.2M as of Apr 1, 2024

Notable Labs, Ltd.

2024-Q1 EPS reported -$0.42 revenue$1,000

Net loss $11.3M ($3.41 per share) vs $14.4M in 2022; revenue $0.3M from diagnostic services.
Cash and equivalents $11.8M at Dec 31, 2023; $8.2M as of Apr 1, 2024; runway into Q4 2024.
R&D expenses fell to $4.7M from $7.8M; G&A rose to $10.1M from $5.2M due to merger costs.
Phase 2 volasertib/PPMP trial for r/r AML to start in coming months with dose-optimization lead-in.
Company became public via reverse merger in October 2023; shares outstanding ~9.0M as of Apr 1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Notable Labs, Ltd. reported the year ended December 31, 2023 results: revenue $0.3 million, net income $(11.3) million, EPS $(3.41) per share.

Period: the year ended December 31, 2023
Revenue: $0.3 million
Net income: $(11.3) million
EPS: $(3.41) per share
Result: reported results

Exact text from the filing

Total net revenue includes revenue from diagnostic services performed on a limited basis as an outsourced provider. Total net revenue for the year ended December 31, 2023 was $0.3 million. Total cost of services relate to the costs of processing diagnostic tests of laboratory samples. Total cost of services for the year ended December 31, 2023 was $0.2 million.

View on SEC.gov

322 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001493152-24-014394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.